EP2297341A4 - METHODS AND COMPOSITIONS FOR THE TREATMENT OF HUNTINGTON'S DISEASE - Google Patents

METHODS AND COMPOSITIONS FOR THE TREATMENT OF HUNTINGTON'S DISEASE

Info

Publication number
EP2297341A4
EP2297341A4 EP09741640A EP09741640A EP2297341A4 EP 2297341 A4 EP2297341 A4 EP 2297341A4 EP 09741640 A EP09741640 A EP 09741640A EP 09741640 A EP09741640 A EP 09741640A EP 2297341 A4 EP2297341 A4 EP 2297341A4
Authority
EP
European Patent Office
Prior art keywords
huntington
disease
compositions
treatment
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP09741640A
Other languages
German (de)
French (fr)
Other versions
EP2297341A1 (en
Inventor
Michael Hayden
Jeffrey Carroll
Simon Warby
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of British Columbia
Original Assignee
University of British Columbia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of British Columbia filed Critical University of British Columbia
Publication of EP2297341A1 publication Critical patent/EP2297341A1/en
Publication of EP2297341A4 publication Critical patent/EP2297341A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP09741640A 2008-05-09 2009-05-08 METHODS AND COMPOSITIONS FOR THE TREATMENT OF HUNTINGTON'S DISEASE Withdrawn EP2297341A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US71465208P 2008-05-09 2008-05-09
PCT/CA2009/000645 WO2009135322A1 (en) 2008-05-09 2009-05-08 Methods and compositions for the treatment of huntington's disease

Publications (2)

Publication Number Publication Date
EP2297341A1 EP2297341A1 (en) 2011-03-23
EP2297341A4 true EP2297341A4 (en) 2013-01-09

Family

ID=41264389

Family Applications (1)

Application Number Title Priority Date Filing Date
EP09741640A Withdrawn EP2297341A4 (en) 2008-05-09 2009-05-08 METHODS AND COMPOSITIONS FOR THE TREATMENT OF HUNTINGTON'S DISEASE

Country Status (4)

Country Link
EP (1) EP2297341A4 (en)
AU (1) AU2009244013B2 (en)
CA (1) CA2726866A1 (en)
WO (1) WO2009135322A1 (en)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2203173T3 (en) 2007-10-26 2016-06-30 Academisch Ziekenhuis Leiden Means and methods for counteracting muscle disorders
EP2119783A1 (en) 2008-05-14 2009-11-18 Prosensa Technologies B.V. Method for efficient exon (44) skipping in Duchenne Muscular Dystrophy and associated means
EP2370451B1 (en) 2008-12-02 2016-11-16 Wave Life Sciences Japan, Inc. Method for the synthesis of phosphorus atom modified nucleic acids
KR101885383B1 (en) 2009-07-06 2018-08-03 웨이브 라이프 사이언시스 리미티드 Novel nucleic acid prodrugs and methods of use thereof
EP3561060A1 (en) * 2010-02-08 2019-10-30 Ionis Pharmaceuticals, Inc. Selective reduction of allelic variants
EP3208347B1 (en) * 2010-02-08 2019-08-14 Ionis Pharmaceuticals, Inc. Selective reduction of allelic variants
US10428019B2 (en) 2010-09-24 2019-10-01 Wave Life Sciences Ltd. Chiral auxiliaries
EP2734208B1 (en) 2011-07-19 2017-03-01 Wave Life Sciences Ltd. Methods for the synthesis of functionalized nucleic acids
EP3556859B1 (en) * 2011-08-11 2021-04-07 Ionis Pharmaceuticals, Inc. Selective antisense compounds and uses thereof
CA2879066C (en) 2012-07-13 2019-08-13 Shin Nippon Biomedical Laboratories, Ltd. Chiral nucleic acid adjuvant
CN104661664B (en) 2012-07-13 2020-07-03 波涛生命科学有限公司 Chiral control
PL2872485T3 (en) 2012-07-13 2021-05-31 Wave Life Sciences Ltd. Asymmetric auxiliary group
WO2014059356A2 (en) 2012-10-12 2014-04-17 Isis Pharmaceuticals, Inc. Selective antisense compounds and uses thereof
CA2899924A1 (en) 2013-02-04 2014-08-07 Isis Pharmaceuticals, Inc. Selective antisense compounds and uses thereof
WO2015108047A1 (en) 2014-01-15 2015-07-23 株式会社新日本科学 Chiral nucleic acid adjuvant having immunity induction activity, and immunity induction activator
JPWO2015108048A1 (en) 2014-01-15 2017-03-23 株式会社新日本科学 Chiral nucleic acid adjuvant and antitumor agent having antitumor activity
JPWO2015108046A1 (en) 2014-01-15 2017-03-23 株式会社新日本科学 Chiral nucleic acid adjuvant and antiallergic agent having antiallergic action
EP4137572A1 (en) 2014-01-16 2023-02-22 Wave Life Sciences Ltd. Chiral design
WO2015164693A1 (en) 2014-04-24 2015-10-29 Isis Pharmaceuticals, Inc. Oligomeric compounds comprising alpha-beta-constrained nucleic acid
MA43072A (en) 2015-07-22 2018-05-30 Wave Life Sciences Ltd COMPOSITIONS OF OLIGONUCLEOTIDES AND RELATED PROCESSES
MA45270A (en) * 2016-05-04 2017-11-09 Wave Life Sciences Ltd COMPOSITIONS OF OLIGONUCLEOTIDES AND RELATED PROCESSES
EP4069846A1 (en) * 2019-12-07 2022-10-12 Scribe Therapeutics Inc. Compositions and methods for the targeting of htt
AU2024220263A1 (en) * 2023-02-17 2025-08-21 Ionis Pharmaceuticals, Inc. Allele-selective compounds and methods for modulating huntingtin expression

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020187931A1 (en) * 2000-04-13 2002-12-12 Michael Hayden Modulating cell survival by modulating huntingtin function
US20100299768A1 (en) * 2007-06-18 2010-11-25 Commissariat A L'energie Atomique Reversible siRNA-Based Silencing of Mutant and Endogenous Wild-Type Huntingtin Gene and its Application for the Treatment of Huntington's Disease

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2062980B1 (en) * 2005-06-28 2011-08-31 Medtronic, Inc. Methods and sequences to preferentially suppress expression of mutated huntingtin gene.
US9273356B2 (en) * 2006-05-24 2016-03-01 Medtronic, Inc. Methods and kits for linking polymorphic sequences to expanded repeat mutations
EP2046993A4 (en) * 2006-07-07 2010-11-17 Univ Massachusetts RNA INTERFERENCE COMPOSITIONS AND METHOD FOR TREATING MORBUS HUNTINGTON

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020187931A1 (en) * 2000-04-13 2002-12-12 Michael Hayden Modulating cell survival by modulating huntingtin function
US20100299768A1 (en) * 2007-06-18 2010-11-25 Commissariat A L'energie Atomique Reversible siRNA-Based Silencing of Mutant and Endogenous Wild-Type Huntingtin Gene and its Application for the Treatment of Huntington's Disease

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DENOVAN-WRIGHT E M ET AL: "RNAi: a potential therapy for the dominantly inherited nucleotide repeat diseases", GENE THERAPY, MACMILLAN PRESS LTD., BASINGSTOKE, GB, vol. 13, no. 6, 1 March 2006 (2006-03-01), pages 525 - 531, XP002452333, ISSN: 0969-7128 *
See also references of WO2009135322A1 *

Also Published As

Publication number Publication date
AU2009244013B2 (en) 2015-06-25
EP2297341A1 (en) 2011-03-23
WO2009135322A1 (en) 2009-11-12
CA2726866A1 (en) 2009-11-12
AU2009244013A1 (en) 2009-11-12

Similar Documents

Publication Publication Date Title
EP2297341A4 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF HUNTINGTON'S DISEASE
EP2367561A4 (en) COMPOSITIONS AND METHODS FOR TREATMENT OF COELIAC DISEASE
EP2209371A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF DIABETIC RETINOPATHY
EP2200616A4 (en) DFO INHIBITORS FOR THE TREATMENT OF HUNTINGTON'S DISEASE AND MULTI-SYSTEMED ATROPHY
EP2224955A4 (en) COMPOSITIONS AND METHODS FOR THE PREVENTION AND TREATMENT OF ARTHRITIS
EP2320937A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF OCULAR OXIDATION STRESS AND PIGMENT RETINITY
EP2341943A4 (en) COMPOSITIONS AND METHODS FOR SPECIFICALLY INHIBITING GENE EXPRESSION BY CHANGES IN THE TREATMENT OF ARNDS
EP2134363A4 (en) COMPOSITIONS AND METHODS FOR TREATING CERVICAL CANCER OF THE UTERUS
EP2352517A4 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF COMPLEMENT RELATED DISORDERS
EP2063889A4 (en) INHIBITORS OF SPIROPIPERIDINE BETA-SECRETASE FOR THE TREATMENT OF ALZHEIMER'S DISEASE
EP2201370A4 (en) COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF TYPE 2 DIABETES
EP2200431A4 (en) NEW COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER
EP2020970A4 (en) TREATMENT OF THE EYE
EP2203057A4 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OR PREVENTION OF INFLAMMATORY CONDITIONS
EP2312945A4 (en) PURINE DERIVATIVES FOR THE TREATMENT OF ALZHEIMER'S DISEASE
EP2459212A4 (en) COMPOSITIONS AND METHODS FOR TREATING LEFT DISEASE
EP2068865A4 (en) METHODS AND COMPOSITIONS FOR THERAPEUTIC TREATMENT
EP2338519A4 (en) TREATMENT AGENT OF MYELFIBROSIS
EP2155249A4 (en) COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF CANCER
EP2063859A4 (en) COSMETIC COMPOSITION FOR SKIN TREATMENT AND RELATED METHODS
EP2182810A4 (en) COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING OSTEOARTHRITIS
EP2217238A4 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF PROTEIN DISEASES
EP2349320A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF RENAL DISORDERS
EP2207892A4 (en) METHODS OF SELECTING ACTIVE AGENTS FOR THE TREATMENT OF CANCER
EP2140882A4 (en) AGENT FOR THE TREATMENT OF PULMONARY DISEASE

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20101209

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA RS

DAX Request for extension of the european patent (deleted)
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1154911

Country of ref document: HK

A4 Supplementary search report drawn up and despatched

Effective date: 20121211

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 25/14 20060101ALI20121205BHEP

Ipc: A61K 31/713 20060101ALI20121205BHEP

Ipc: C12Q 1/68 20060101AFI20121205BHEP

Ipc: A61K 31/7088 20060101ALI20121205BHEP

Ipc: C12N 15/85 20060101ALI20121205BHEP

Ipc: G01N 33/53 20060101ALI20121205BHEP

Ipc: C07H 21/00 20060101ALI20121205BHEP

Ipc: C12N 15/63 20060101ALI20121205BHEP

Ipc: C12N 15/11 20060101ALI20121205BHEP

Ipc: G01N 33/68 20060101ALI20121205BHEP

17Q First examination report despatched

Effective date: 20150511

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20170523

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1154911

Country of ref document: HK